{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:33:46Z","timestamp":1793126026321,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107642","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:58:05Z","timestamp":1786805885000},"page":"107642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sustained drug exposure drives efficacy in mice: PK\/PD analysis of corallopyronin a against wolbachia using physiologically based absorption modeling"],"prefix":"10.1016","volume":"227","author":[{"given":"J.","family":"Heitk\u00f6tter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Risch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u202fP.","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kehraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-7191","authenticated-orcid":false,"given":"K.\u202fG.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107642_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1521091","article-title":"Enhancing antibiotic therapy through comprehensive pharmacokinetic\/pharmacodynamic principles","volume":"15","author":"Alikhani","year":"2025","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107642_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000217","article-title":"Of mice, cattle, and humans: the immunology and treatment of river blindness","volume":"2","author":"Allen","year":"2008","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"9","key":"10.1016\/j.ejps.2026.107642_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030371","article-title":"River blindness: a success story under threat?","volume":"3","author":"Bas\u00e1\u00f1ez","year":"2006","journal-title":"PLoS. Med."},{"issue":"8","key":"10.1016\/j.ejps.2026.107642_bib0004","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/pharmaceutics14081657","article-title":"In vitro-In vivo relationship in mini-scale-enabling formulations of corallopyronin A","volume":"14","author":"Becker","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107642_bib0005","author":"Becker"},{"issue":"9","key":"10.1016\/j.ejps.2026.107642_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012929","article-title":"Fexinidazole and corallopyronin A target wolbachia-infected sheath cells present in filarial nematodes","volume":"21","author":"Chappell","year":"2025","journal-title":"PLoS. Pathog."},{"issue":"3","key":"10.1016\/j.ejps.2026.107642_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tim.2023.08.009","article-title":"Host cell environments and antibiotic efficacy in tuberculosis","volume":"32","author":"Day","year":"2024","journal-title":"Trends. Microbiol."},{"issue":"12","key":"10.1016\/j.ejps.2026.107642_bib0008","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1365-3156.2007.01949.x","article-title":"Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti","volume":"12","author":"Debrah","year":"2007","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ejps.2026.107642_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2022.983107","article-title":"Pharmacology and early ADMET data of corallopyronin A, a natural product with macrofilaricidal anti-wolbachial activity in filarial nematodes","volume":"3","author":"Ehrens","year":"2022","journal-title":"Front. Trop. Dis."},{"issue":"6","key":"10.1016\/j.ejps.2026.107642_bib0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","article-title":"The Hill equation: a review of its capabilities in pharmacological modelling","volume":"22","author":"Goutelle","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107642_bib0011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1365-2958.2009.06815.x","article-title":"Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?","volume":"73","author":"Henrichfreise","year":"2009","journal-title":"Mol. Microbiol."},{"issue":"9","key":"10.1016\/j.ejps.2026.107642_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0169-4758(00)01738-5","article-title":"Litomosoides sigmodontis in mice: reappraisal of an old model for filarial research","volume":"16","author":"Hoffmann","year":"2000","journal-title":"Parasitol. Today"},{"issue":"4","key":"10.1016\/j.ejps.2026.107642_bib0013","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1073\/pnas.1816585116","article-title":"AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis","volume":"116","author":"Hong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.ejps.2026.107642_bib0014","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"Hotez","year":"2007","journal-title":"N. Engl. J.Med."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006320","article-title":"Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds","volume":"13","author":"H\u00fcbner","year":"2019","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"8","key":"10.1016\/j.ejps.2026.107642_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007636","article-title":"In vivo kinetics of wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae","volume":"13","author":"H\u00fcbner","year":"2019","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"7","key":"10.1016\/j.ejps.2026.107642_bib0017","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of Rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob. Agent. Chemother"},{"issue":"4","key":"10.1016\/j.ejps.2026.107642_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01732-17","article-title":"Orientia tsutsugamushi is highly susceptible to the RNA polymerase switch region inhibitor corallopyronin A In vitro and In vivo","volume":"62","author":"Kock","year":"2018","journal-title":"Antimicrob. Agent. Chemother."},{"issue":"9","key":"10.1016\/j.ejps.2026.107642_bib0019","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1039\/D2NP00012A","article-title":"Corallopyronin A: antimicrobial discovery to preclinical development","volume":"39","author":"Krome","year":"2022","journal-title":"Nat. Prod. Rep."},{"issue":"11","key":"10.1016\/j.ejps.2026.107642_bib0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/pharmaceutics12111105","article-title":"Solubility and stability enhanced oral formulations for the anti-infective corallopyronin A","volume":"12","author":"Krome","year":"2020","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.ejps.2026.107642_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002351","article-title":"Anti-filarial activity of antibiotic therapy is due to extensive apoptosis after wolbachia depletion from filarial nematodes","volume":"7","author":"Landmann","year":"2011","journal-title":"PLoS. Pathog."},{"issue":"10\u201311","key":"10.1016\/j.ejps.2026.107642_bib0022","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennern\u00e4s","year":"2007","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.ejps.2026.107642_bib0023","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/acs.molpharmaceut.4c00202","article-title":"Physiologically based Biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report","volume":"21","author":"Mackie","year":"2024","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2026.107642_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1208\/s12248-011-9303-8","article-title":"Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems","volume":"13","author":"Martinez","year":"2011","journal-title":"AAPS. J."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jps.2600700103","article-title":"Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions","volume":"70","author":"Mooney","year":"1981","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jps.2600700104","article-title":"Dissolution kinetics of carboxylic acids II: effect of buffers","volume":"70","author":"Mooney","year":"1981","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/antibiotics14010092","article-title":"PK\/PD-guided strategies for appropriate antibiotic use in the era of antimicrobial resistance","volume":"14","author":"Onita","year":"2025","journal-title":"Antibiotics"},{"issue":"4","key":"10.1016\/j.ejps.2026.107642_bib0028","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/acs.molpharmaceut.3c00005","article-title":"Acalabrutinib maleate tablets: the physiologically based biopharmaceutics model behind the drug product dissolution specification","volume":"20","author":"Pepin","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107642_bib0029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejpb.2019.07.014","article-title":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input","volume":"142","author":"Pepin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13071-023-05909-8","article-title":"The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use","volume":"16","author":"Pfarr","year":"2023","journal-title":"Parasit. Vect."},{"key":"10.1016\/j.ejps.2026.107642_bib0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ymben.2019.07.010","article-title":"Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic","volume":"55","author":"Pogorevc","year":"2019","journal-title":"Metab. Eng."},{"issue":"12","key":"10.1016\/j.ejps.2026.107642_bib0032","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s00436-020-07026-2","article-title":"Human filariasis\u2014contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model","volume":"120","author":"Risch","year":"2021","journal-title":"Parasitol. Res."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0033","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/pharmaceutics15010131","article-title":"Pharmacokinetics and pharmacodynamics (PK\/PD) of corallopyronin A against methicillin-resistant Staphylococcus aureus","volume":"15","author":"Rox","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijmm.2013.08.010","article-title":"Corallopyronin a \u2013 a promising antibiotic for treatment of filariasis","volume":"304","author":"Sch\u00e4berle","year":"2014","journal-title":"Intern. J. Med. Microbiol."},{"issue":"10","key":"10.1016\/j.ejps.2026.107642_bib0035","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1021\/acs.jnatprod.5b00175","article-title":"Insights into structure\u2013Activity relationships of bacterial RNA polymerase inhibiting corallopyronin derivatives","volume":"78","author":"Sch\u00e4berle","year":"2015","journal-title":"J. Nat. Prod."},{"issue":"12","key":"10.1016\/j.ejps.2026.107642_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008930","article-title":"Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections","volume":"14","author":"Schiefer","year":"2020","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.ejps.2026.107642_bib0037","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/infdis\/jis341","article-title":"Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo","volume":"206","author":"Schiefer","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejps.2026.107642_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124481","article-title":"Experimental and computational analysis of lipophilicity and plasma protein binding properties of potent tacrine based cholinesterase inhibitors","volume":"1253","author":"\u0160egan","year":"2025","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.ejps.2026.107642_bib0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jps.2600740209","article-title":"Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts II: salicylic acid, theophylline, and benzoic acid","volume":"74","author":"Serajuddin","year":"1985","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006116","article-title":"Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model","volume":"12","author":"Specht","year":"2018","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.ejps.2026.107642_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006116","article-title":"Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model","volume":"12","author":"Specht","year":"2018","journal-title":"PLoS. Negl. Trop. Dis."},{"issue":"17","key":"10.1016\/j.ejps.2026.107642_bib0042","doi-asserted-by":"crossref","first-page":"R797","DOI":"10.1016\/j.cub.2016.07.045","article-title":"Endosymbiosis: the remarkable healing powers of Wolbachia","volume":"26","author":"Sullivan","year":"2016","journal-title":"Curr. Biol."},{"issue":"483","key":"10.1016\/j.ejps.2026.107642_bib0043","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau2086","article-title":"Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis","volume":"11","author":"Taylor","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.ejps.2026.107642_bib0044","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/501351","article-title":"A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection","volume":"42","author":"Turner","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ejps.2026.107642_bib0045","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jps.23592","article-title":"Rational development of solid dispersions via hot-melt extrusion using screening, material characterization, and numeric simulation tools","volume":"102","author":"Zecevic","year":"2013","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:51:49Z","timestamp":1793123509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S0928098726002162"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107642","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained drug exposure drives efficacy in mice: PK\/PD analysis of corallopyronin a against wolbachia using physiologically based absorption modeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107642"}}